Solutions
Transforming Access from Strategy to Operational Execution
From helping emerging companies plan and execute their first-time launch, to supporting more than 65% of the Top 50 largest manufacturers, IntegriChain’s solutions have helped manufacturers unify market access teams and solve complex market access business challenges.
Through IntegriChain’s ICyte platform, historically siloed Market Access functions – commercial teams focused on payers and patient access; operational teams focused on contract management and pricing; and finance teams focused on gross-to-net forecasting and accruals – are able to come together through shared data, eliminating manual processes and disparate system that often hold these teams back from innovating and transforming access to their therapies.
Blue Fin Group and IntegriChain help ensure your strategy is on point for your product archetype and therapeutic class.
Webinar
State Price Transparency: 2022 Legislative and Regulatory Overview
IntegriChain subject matter experts discuss the current status of drug pricing transparency laws that have been recently introduced and updated at the state level. Topics include disclosures themes, types of reports, and new reporting updates for nearly a dozen states.
Watch THE WEBINAR
Paper
The Case for Gross-to-Net Automation
As the GTN bubble grows, so does increased stakeholder scrutiny on GTN analytics. Although the industry is moving toward automation, many life sciences manufacturers are currently analyzing their options, the value automation brings to the organization, and making a business case to management.
READ Paper